EUVIMEDEUVIMED entdecken
Crossref

Scopoletin Mitigates DSS‐Induced Ulcerative Colitis by Attenuating NF‐κB/MMP‐9 Mediated Inflammation and Activating the Nrf2 Pathway to Preserve Colonic Barrier Integrity

A Gowtham iD, Tushar Mishra, Tarh Gungha, Ravinder K Kaundal iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von A Gowtham und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-R), Transit Campus, Bijnor-S…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, NF-E2-Related Factor 2, Scopoletin, Anti-Inflammatory Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ulcerative colitis (UC) is a chronic inflammatory disorder of the colon, characterized by persistent mucosal inflammation and epithelial barrier disruption. This study investigated the therapeutic efficacy of Scopoletin, a natural coumarin derivative with established anti‐inflammatory and antioxidant properties, in a DSS‐induced colitis model in Balb/c mice. A total of five experimental groups were established: a normal control, a DSS+ vehicle group, two Scopoletin‐treated groups (10 and 30 mg/kg), and a reference group treated with Sulfasalazine (200 mg/kg). Network pharmacology analyses identified key inflammatory and immune‐regulatory pathways potentially modulated by Scopoletin. In vivo assessments encompassed body weight monitoring, DAI scoring, colon length measurement, and histopathological evaluation using H&E, PAS, and Alcian blue staining. Scopoletin (30 mg/kg) treatment significantly ameliorated clinical and histological manifestations of colitis, including body weight loss and colonic shortening. Mechanistically, Scopoletin (30 mg/kg) attenuated the expression of pro‐inflammatory cytokines such as TNF‐α and IL‐1β, suppressed NF‐κB activation, MMP‐9, COX‐2 and enhanced the Nrf2 expression, leading to upregulation of antioxidant enzymes HO‐1 and NQO1. Notably, Scopoletin (30 mg/kg) restored the expression of tight junction proteins such as Occludin and ZO‐1, indicating reinforcement of epithelial barrier integrity. These findings demonstrated that Scopoletin protects against UC by suppressing inflammation, enhancing antioxidant defenses, and preserving mucosal barrier integrity, highlighting its potential as a therapeutic candidate for UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeNF-E2-Related Factor 2ScopoletinAnti-Inflammatory AgentsAnimalsNF-kappa BMice, Inbred BALB CMiceDextran SulfateMatrix Metalloproteinase 9ColonMaleDisease Models, AnimalSignal TransductionInflammationIntestinal Mucosa

Stichwörter der Autor:innen

ScopoletinUlcerative colitiscolon barrier integrityinflammation

Substanzen

NF-E2-Related Factor 2NF-kappa BScopoletinNfe2l2 protein, mouseDextran SulfateMatrix Metalloproteinase 9Anti-Inflammatory AgentsMmp9 protein, mouse

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-R), Transit Campus, Bijnor-Sisendi Road, Sarojini Nagar, Near CRPF Base Camp, Lucknow (UP)- 226002.

ORCID-Profile: A Gowtham, Ravinder K Kaundal

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Gowtham, A., Mishra, T., Gungha, T., & Kaundal, R. K. (2025). Scopoletin Mitigates DSS‐Induced Ulcerative Colitis by Attenuating NF‐κB/MMP‐9 Mediated Inflammation and Activating the Nrf2 Pathway to Preserve Colonic Barrier Integrity. Drug Development Research. https://doi.org/10.1002/ddr.70165

Vancouver

Gowtham A, Mishra T, Gungha T, Kaundal RK. Scopoletin Mitigates DSS‐Induced Ulcerative Colitis by Attenuating NF‐κB/MMP‐9 Mediated Inflammation and Activating the Nrf2 Pathway to Preserve Colonic Barrier Integrity. Drug Development Research. 2025. doi:10.1002/ddr.70165

BibTeX
@article{Gowtham2025,
  author = {Gowtham, A and Mishra, Tushar and Gungha, Tarh and Kaundal, Ravinder K},
  title = {Scopoletin Mitigates DSS‐Induced Ulcerative Colitis by Attenuating NF‐κB/MMP‐9 Mediated Inflammation and Activating the Nrf2 Pathway to Preserve Colonic Barrier Integrity},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70165}
}
Kostenlos starten →